Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: Prediction of in vivo drug interactions

Xenobiotica

Volumn 35, Issue 6, 2005, Pages 549-560

  Hara, Y ^a,b   Nakajima, M ^a   Miyamoto, K I ^b   Yokoi, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cytochrome P450; Inactivation; Inhibition; Mexiletine; Psychotropic drug

Indexed keywords

CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; ETIZOLAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MEXILETINE; OLANZAPINE; PAROXETINE; PHENYTOIN; PSYCHOTROPIC AGENT; QUAZEPAM; SERTRALINE; THIORIDAZINE;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME;

ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME ACTIVATION; HUMANS; HYDROXYLATION; METABOLIC CLEARANCE RATE; MEXILETINE; MICROSOMES, LIVER; PREDICTIVE VALUE OF TESTS; PSYCHOTROPIC DRUGS;

EID: 24144469741     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500158134     Document Type: Article

References (56)

1. Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. 2001. Psychiatric disorders and associated and predictive factors in patients with unresectable non small cell lung carcinoma: A longitudinal study. Cancer 92:2609-2622.
2. Altamura AC, Moro AR, Percudani M. 1994. Clinical pharmacokinetics of fluoxetine. Clinical Pharmacokinetics 26:201-214.
3. Apple FS, Bandt CM. 1988. Liver and blood postmortem tricyclic antidepressant concentrations. American Journal of Clinical Pathology 89:794-796.
4. Araki K, Yasui N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K. 2004. Inhibition of the metabolism of etizolam by itraconazole in humans: Evidence for the involvement of CYP3A4 in etizolam metabolism. European Journal of Clinical Pharmacology 60:427-430.
5. Bajpai M, Roskos LK, Shen DD, Levy RH. 1996. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metabolism and Disposition 24:1401-1403.
6. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. 2003. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metabolism and Disposition 31:289-293.
7. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. 1992. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. British Journal of Clinical Pharmacology 33:521-523.
8. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. 1993. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. European Journal of Clinical Pharmacology 44:349-355.
9. Brown CS, Farmer RG, Soberman JE, Eichner SF. 2004. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clinical Pharmacokinetics 43:33-56.
10. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. 1999. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 37:177-193.
11. Campbell NP, Kelly JG, Adgey AA, Shanks RG. 1978. The clinical pharmacology of mexiletine. British Journal of Clinical Pharmacology 6:103-108.
12. Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JA, Berecz R, Duran M, Benitez J. 1999. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. Journal of Clinical Psychopharmacology 19:494-499.
13. Chakraborty BS, Midha KK, McKay G, Hawes EM, Hubbard JW, Korchinski ED, Choc MG, Robinson WT. 1989. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: A dose proportionality study. Journal of Pharmaceutical Sciences 78:796-801.
14. Cooper SF, Dugal R, Elie R, Albert JM. 1979. Metabolic interaction between amitriptyline and perphenazine in psychiatric patients. Progress in Neuropsychopharmacology 3:369-376.
15. DeVane CL, Liston HL, Markowitz JS. 2002. Clinical pharmacokinetics of sertraline. Clinical Pharmacokinetics 41:1247-1266.
16. Dinovo EC, Bost RO, Sunshine I, Gottschalk LA. 1978. Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. Clinical Chemistry 24:1828-1830.
17. Eap CB, Guentert TW, Schaublin-Loidl M, Stabl M, Koeb L, Powell K, Baumann P. 1996. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clinical Pharmacology and Therapeutics 59:322-331.
18. Fang J, Baker GB, Silverstone PH, Courts RT. 1997. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cellular and Molecular Neurobiology 17:227-233.
19. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brosen K. 1999. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 9:55-60.
20. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. 2004. Diabetes, depression, and quality of life: A population study. Diabetes Care 27:1066-1070.
21. Gram LF, Overo K, Kirk L. 1974. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. American Journal of Psychiatry 131:863-866.
22. Guengerich FP. 1997. Role of cytochrome P450 enzymes in drug-drug interactions. Advance in Pharmacology 43:7-35.
23. Harten J. 1995. Overview of the pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics 29:1-9.
24. Ito K, Ogihara K, Kanamitsu S, Itoh T. 2003. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metabolism and Disposition 31:945-954.
25. Kanamitsu S, Ito K, Okuda H, Ogura K, Watabe T, Muro K, Sugiyama Y. 2000. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl) uracil. Drug Metabolism and Disposition 28:467-474.
26. Kato K, Yasui N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K. 2003. Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. Therapeutic Drug Monitoring 25:473-477.
27. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH. 1989. A review of themetabolism and pharmacokinetics of paroxetine in man. Acta Psychiatrica Scandinavica Supplementum 350:60-75.
28. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. 1994. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical Pharmacology 47:1969-1979.
29. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y. 1997. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 280:927-233.
30. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. 1999. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metabolism and Disposition 27:763-766.
31. Kugaya A, Akechi T, Okuyama T, Nakano T, Mikami I, Okamura H, Uchitomi Y. 2000. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 88:2817-2823.
32. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. 1997. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clinical Pharmacology and Therapeutics 62:145-156.
33. Labbé L, Turgeon J. 1999. Clinical pharmacokinetics of mexiletine. Clinical Pharmacokinetics 37:361-384.
34. Lane RM. 1996. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. International Clinical Psychopharmacology 11:31-61.
35. Levine B, Jenkins AJ, Smialek JE. 1994. Distribution of sertraline in postmortem cases. Journal of Analytical Toxicology 18:272-274.
36. Lin JH, Lu AY. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics 35:361-390.
37. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS. 2000. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metabolism and Disposition 28:1187-1191.
38. Mayhew BS, Jones DR, Hall SD. 2000. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition 28:1031-1037.
39. Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. 1998. Involvement of CYP1A2 in mexiletine metabolism. British Journal of Clinical Pharmacology 46:55-62.
40. Nakajima M, Suzuki M, Yamaji R, Takashina H, Shimada N, Yamazaki H, Yokoi T. 1999. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica 29:1191-1202.
41. Nyberg G, Axelsson R, Martensson E. 1978. Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. European Journal of Clinical Pharmacology 14:341-350.
42. Okamura H, Watanabe T, Narabayashi M, Katsumata N, Ando M, Adachi I, Akechi T, Uchitomi Y. 2000. Psychological distress following first recurrence of disease in patients with breast cancer: Prevalence and risk factors. Breast Cancer Research and Treatment 61:131-137.
43. Ortiz de Montellano PR, Correia MA. 1995. Inhibition of cytochrome P450 enzymes. In: PR Ortiz de Montellano, editor. Cytochrome P450 structure, mechanism and biochemistry. New York: Plenum, pp 305-366.
44. Otani M, Fukuda T, Naohara M, Maune H, Senda C, Yamamoto I, Azuma J. 2003. Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. European Journal of Clinical Pharmacology 59:395-399.
45. Paczkowski D, Sadowski Z, Filipek M, Kolinski P. 1990. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. Polish Journal of Pharmacology and Pharmacy 42:365-375.
46. Pan LP, Wijnant P, Vriendt C, Rosseel MT, Belpaire FM. 1997. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. British Journal of Clinical Pharmacology 44:557-564.
47. Preskorn SH. 1998. Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytocbrome P450 enzymes. Journal of Psychopharmacology 12:889-97.
48. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA. 1996. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Journal of Pharmacology and Experimental Therapeutics 276:658-666.
49. Sallee FR, Pollock BG. 1990. Clinical pharmacokinetics of imipramine and desipramine. Clinical Pharmacokinetics 18:346-364.
50. Segel IH, editor. 1993. Rapid equilibrium partial and mixed type inhibition. In: Enzyme kinetics. New York: Wiley-Interscience. pp 161-226.
51. Silverman RB, editor. 1988. Mechanism-based enzyme inactivation. In: Chemistry and enzymology. Vol. 1. Boca Raton, FL: CRC Press, pp 3-30.
52. Skjelbo E, Brosen K. 1992. Inhibitors of imipramine metabolism by human liver microsomes. British Journal of Clinical Pharmacology 34:256-261.
53. Uchitomi Y, Mikami I, Nagai K, Nishiwaki, Y, Akechi T, Okamura H. 2003. Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. Journal of Clinical Oncology 21:69-77.
54. Vanderheeren FA, Muusze RG. 1977. Plasma levels and half lives of thioridazine and some of its metabolites I. High doses in young acute schizophrenics. European Journal of Clinical Pharmacology 11:135-140.
55. Vermeulen T. 1998. Distribution of paroxetine in three postmortem cases. Journal of Analytical Toxicology 22:541-544.
56. Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. 1995. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. Journal of Clinical Psychopharmacology 15:125-131.